<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:58:00Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7845614" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7845614</identifier>
        <datestamp>2021-01-29</datestamp>
        <setSpec>msphere</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">mSphere</journal-id>
              <journal-id journal-id-type="iso-abbrev">mSphere</journal-id>
              <journal-id journal-id-type="hwp">msph</journal-id>
              <journal-id journal-id-type="pmc">msph</journal-id>
              <journal-id journal-id-type="publisher-id">mSphere</journal-id>
              <journal-title-group>
                <journal-title>mSphere</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2379-5042</issn>
              <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
                <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7845614</article-id>
              <article-id pub-id-type="pmcid">PMC7845614</article-id>
              <article-id pub-id-type="pmc-uid">7845614</article-id>
              <article-id pub-id-type="pmid">33441409</article-id>
              <article-id pub-id-type="publisher-id">mSphere00936-20</article-id>
              <article-id pub-id-type="doi">10.1128/mSphere.00936-20</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="overline">
                  <subject>Host-Microbe Biology</subject>
                </subj-group>
                <subj-group subj-group-type="editorial-class">
                  <subject>Editor's Pick</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Randomized Controlled Trial of Oral Vancomycin Treatment in <named-content content-type="genus-species">Clostridioides difficile</named-content>-Colonized Patients</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9554-1170</contrib-id>
                  <name>
                    <surname>Fishbein</surname>
                    <given-names>Skye R. S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>a</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>b</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hink</surname>
                    <given-names>Tiffany</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reske</surname>
                    <given-names>Kimberly A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cass</surname>
                    <given-names>Candice</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Struttmann</surname>
                    <given-names>Emily</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iqbal</surname>
                    <given-names>Zainab Hassan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Seiler</surname>
                    <given-names>Sondra</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kwon</surname>
                    <given-names>Jennie H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1137-840X</contrib-id>
                  <name>
                    <surname>Burnham</surname>
                    <given-names>Carey-Ann D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>b</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff4">
                    <sup>d</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff5">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0455-8370</contrib-id>
                  <name>
                    <surname>Dantas</surname>
                    <given-names>Gautam</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>a</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>b</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff4">
                    <sup>d</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff6">
                    <sup>f</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Dubberke</surname>
                    <given-names>Erik R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <aff id="aff1">
                  <label>a</label>
                  <addr-line>The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
                <aff id="aff2">
                  <label>b</label>
                  <addr-line>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
                <aff id="aff3">
                  <label>c</label>
                  <addr-line>Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
                <aff id="aff4">
                  <label>d</label>
                  <addr-line>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
                <aff id="aff5">
                  <label>e</label>
                  <addr-line>Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
                <aff id="aff6">
                  <label>f</label>
                  <addr-line>Department of Biomedical Engineering, Washington University School of Medicine, St. Louis, Missouri, USA</addr-line>
                </aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Young</surname>
                    <given-names>Vincent B.</given-names>
                  </name>
                  <role>Editor</role>
                  <aff>University of Michigan-Ann Arbor</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Address correspondence to Gautam Dantas, <email>dantas@wustl.edu</email>, or Erik R. Dubberke, <email>edubberk@wustl.edu</email>.</corresp>
                <fn fn-type="other">
                  <p><bold>Citation</bold> Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, Seiler S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. 2021. Randomized controlled trial of oral vancomycin treatment in <italic>Clostridioides difficile</italic>-colonized patients. mSphere 6:e00936-20. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mSphere.00936-20">https://doi.org/10.1128/mSphere.00936-20</ext-link>.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>1</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <season>Jan-Feb</season>
                <year>2021</year>
              </pub-date>
              <volume>6</volume>
              <issue>1</issue>
              <elocation-id>e00936-20</elocation-id>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Fishbein et al.</copyright-holder>
                <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="mSphere.00936-20.pdf"/>
              <abstract abstract-type="precis">
                <p>A gold standard diagnostic for <named-content content-type="genus-species">Clostridioides difficile</named-content> infection (CDI) does not exist. An area of controversy is how to manage patients whose stool tests positive by nucleic acid amplification tests but negative by toxin enzyme immunoassay.</p>
              </abstract>
              <abstract>
                <title>ABSTRACT</title>
                <p><named-content content-type="genus-species">Clostridioides difficile</named-content> infection (CDI) is most commonly diagnosed using nucleic acid amplification tests (NAAT); the low positive predictive value of these assays results in patients colonized with <named-content content-type="genus-species">C. difficile</named-content> unnecessarily receiving CDI treatment antibiotics. The risks and benefits of antibiotic treatment in individuals with such cases are unknown. Fecal samples of NAAT-positive, toxin enzyme immunoassay (EIA)-negative patients were collected before, during, and after randomization to vancomycin (<italic>n</italic> = 8) or placebo (<italic>n</italic> = 7). <named-content content-type="genus-species">C. difficile</named-content> and antibiotic-resistant organisms (AROs) were selectively cultured from fecal and environmental samples. Shotgun metagenomics and comparative isolate genomics were used to understand the impact of oral vancomycin on the microbiome and environmental contamination. Overall, 80% of placebo patients and 71% of vancomycin patients were colonized with <named-content content-type="genus-species">C. difficile</named-content> posttreatment. One person randomized to placebo subsequently received treatment for CDI. In the vancomycin-treated group, beta-diversity (<italic>P = </italic>0.0059) and macrolide-lincosamide-streptogramin (MLS) resistance genes (<italic>P = </italic>0.037) increased after treatment; <named-content content-type="genus-species">C. difficile</named-content> and vancomycin-resistant enterococci (VRE) environmental contamination was found in 53% of patients and 26% of patients, respectively. We found that vancomycin alters the gut microbiota, does not permanently clear <named-content content-type="genus-species">C. difficile</named-content>, and is associated with VRE colonization/environmental contamination. (This study has been registered at ClinicalTrials.gov under registration no. NCT03388268.)</p>
                <p><bold>IMPORTANCE</bold> A gold standard diagnostic for <named-content content-type="genus-species">Clostridioides difficile</named-content> infection (CDI) does not exist. An area of controversy is how to manage patients whose stool tests positive by nucleic acid amplification tests but negative by toxin enzyme immunoassay. Existing data suggest most of these patients do not have CDI, but most are treated with oral vancomycin. Potential benefits to treatment include a decreased risk for adverse outcomes if the patient does have CDI and the potential to decrease <named-content content-type="genus-species">C. difficile</named-content> shedding/transmission. However, oral vancomycin perturbs the intestinal microbiota and promotes antibiotic-resistant organism colonization/transmission. We conducted a double-blinded randomized controlled trial to assess the risk-benefit of oral vancomycin treatment in this population. Oral vancomycin did not result in long-term clearance of <named-content content-type="genus-species">C. difficile</named-content>, perturbed the microbiota, and was associated with colonization/shedding of vancomycin-resistant enterococci. This work underscores the need to better understand this population of patients in the context of <named-content content-type="genus-species">C. difficile</named-content>/ARO-related outcomes and transmission.</p>
              </abstract>
              <kwd-group>
                <title>KEYWORDS</title>
                <kwd>
                  <italic>C. difficile</italic>
                </kwd>
                <kwd>vancomycin-resistant enterococci</kwd>
                <kwd>vancomycin</kwd>
              </kwd-group>
              <counts>
                <count count="10" count-type="supplementary-material"/>
                <fig-count count="3"/>
                <table-count count="1"/>
                <equation-count count="0"/>
                <ref-count count="44"/>
                <page-count count="12"/>
                <word-count count="7466"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January/February 2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>The CDC estimates there were 223,900 cases of <named-content content-type="genus-species">Clostridioides difficile</named-content> infection (CDI) requiring hospitalization in 2017 in the United States (<xref rid="B1" ref-type="bibr">1</xref>). Previous antibiotic use, chemotherapy, and an extended stay in a health care facility are associated with CDI (<xref rid="B2" ref-type="bibr">2</xref>). Concomitantly, such risk factors are associated with colonization by antibiotic-resistant organisms (AROs), which cause significant mortality and burden on the health care system (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Interventions such as increasing antibiotic stewardship and decreasing organism transmission are associated with reductions in CDI incidence and ARO infections (<xref rid="B5" ref-type="bibr">5</xref>).</p>
              <p>Diagnosis of CDI remains a significant challenge, as <named-content content-type="genus-species">C. difficile</named-content> can cause a spectrum of illnesses in patients, from asymptomatic colonization to diarrhea, fulminant colitis, and death (<xref rid="B6" ref-type="bibr">6</xref>). Initially, toxin enzyme immunoassays (EIAs) were the most commonly used diagnostic assay, but they suffered from low analytical sensitivity (<xref rid="B7" ref-type="bibr">7</xref>). In response, nucleic acid amplification tests (NAATs) that detect <named-content content-type="genus-species">C. difficile</named-content> toxin DNA in stool were developed with increased analytical sensitivity compared to that of toxin EIAs. Due to this enhanced sensitivity, NAAT assays are more likely than EIAs to detect <named-content content-type="genus-species">C. difficile</named-content> colonization in the absence of CDI (<xref rid="B8" ref-type="bibr">8</xref>). In turn, a significant proportion of patients whose stool tests EIA negative/NAAT positive (EIA<sup>−</sup>/NAAT<sup>+</sup>) are considered asymptomatic carriers, with diarrhea from other causes (<xref rid="B9" ref-type="bibr">9</xref>). When NAATs are used for diagnostic testing, most patients with NAAT-positive stool receive treatment for CDI (<xref rid="B10" ref-type="bibr">10</xref>).</p>
              <p>Oral vancomycin is a first-line, widely accepted treatment for CDI (<xref rid="B11" ref-type="bibr">11</xref>). While there is a clear benefit to administering oral vancomycin when a patient has CDI, the risk-benefit balance of oral vancomycin when administered to EIA<sup>−</sup>/NAAT<sup>+</sup> patients is less clear. If the EIA is falsely negative for CDI, one benefit of treating EIA<sup>−</sup>/NAAT<sup>+</sup> patients is the potential avoidance of CDI-associated adverse outcomes, such as sepsis, toxic megacolon, and death (<xref rid="B12" ref-type="bibr">12</xref>). Oral vancomycin has been found to reduce shedding of <named-content content-type="genus-species">C. difficile</named-content> in feces of colonized patients (<xref rid="B13" ref-type="bibr">13</xref>), potentially reducing contamination of their hospital environment (environmental contamination) and <named-content content-type="genus-species">C. difficile</named-content> transmission to other patients. However, antibiotics disturb the gut microbiota, increase the risk of CDI, and also can affect the composition of resistance gene determinants (the resistome) in the gut microbiota (<xref rid="B14" ref-type="bibr">14</xref><xref ref-type="bibr" rid="B15">–</xref><xref rid="B16" ref-type="bibr">16</xref>). Further, oral vancomycin is associated with colonization and expansion of vancomycin-resistant enterococci (VRE) in CDI-treated patients (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). These expansions may increase the risk of subsequent infection in the patient as well as environmental contamination by the colonized patient and subsequent transmission.</p>
              <p>In this study, we performed a double-blinded randomized control trial to examine the effect of oral vancomycin on <named-content content-type="genus-species">C. difficile</named-content>-colonized patients (EIA<sup>−</sup>/NAAT<sup>+</sup>). Specifically, we analyzed patient gut communities over time to understand the extent of microbiome and resistome alterations correlated with vancomycin treatment. Additionally, we examined the influence of this treatment on <named-content content-type="genus-species">C. difficile</named-content> and ARO environmental contamination.</p>
            </sec>
            <sec sec-type="results" id="s2">
              <title>RESULTS</title>
              <sec id="s2.1">
                <title>Study population and sample collection.</title>
                <p>The charts of 3,089 patients whose stool tested EIA<sup>−</sup> were reviewed, and of those patients, 648 were eligible for NAAT testing. Of these, 65 (10%) were NAAT<sup>+</sup>, and 15 were enrolled. Eight were randomized to receive oral vancomycin (see <xref ref-type="supplementary-material" rid="figS1">Fig. S1</xref> in the supplemental material). The majority (80%) of patients had previous hospitalizations (<xref rid="tab1" ref-type="table">Table 1</xref>). At enrollment and during treatment, 71% of patients in the placebo group received nonstudy antibiotics relative to 88% in the vancomycin group (<xref ref-type="supplementary-material" rid="figS2">Fig. S2a</xref>). Fecal samples (or rectal swabs if fecal samples were not available) and environmental samples were collected from patients and their environments (<xref ref-type="fig" rid="fig1">Fig. 1a</xref>), and the microbiomes were analyzed for patients with specimens from at least three time points (<xref ref-type="supplementary-material" rid="textS1">Text S1</xref>). Therefore, patients 4, 5, and 6 were excluded.</p>
                <fig id="fig1" orientation="portrait" position="float">
                  <label>FIG 1</label>
                  <caption>
                    <p>Vancomycin effect on <named-content content-type="genus-species">C. difficile</named-content>-colonized patient gut microbiomes. (a) Randomized control trial to test the effect of 10 days of oral vancomycin treatment on health-related outcomes in <named-content content-type="genus-species">C. difficile</named-content>-colonized patients. Patient stool and surfaces were sampled to examine patient microbiomes and environmental contamination of hospital environments. (b) Beta-diversity, as measured by Bray-Curtis dissimilarity, distributions of within-patient comparisons between placebo and vancomycin treatment groups. Dissimilarity was significantly different between treatment groups (**, <italic>P</italic> = 0.0057) as measured by a Wilcoxon rank sum test. (c) Measurement of alpha-diversity (richness) of microbial species in patient fecal samples over time due to vancomycin treatment. Richness was not significantly affected by vancomycin treatment (<italic>P</italic> = 0.23), as examined by a two-way analysis of variance. (d) Relative abundance of major antibiotic resistance (AMR) classes before (index) and after (week 8) treatment, averaged across patients. MLS, macrolide-lincosamide-streptogramin.</p>
                  </caption>
                  <graphic xlink:href="mSphere.00936-20_f001"/>
                </fig>
                <table-wrap id="tab1" orientation="portrait" position="float">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Patient demographics<xref ref-type="table-fn" rid="ngtab1.1"><sup><italic>a</italic></sup></xref></p>
                  </caption>
                  <alternatives>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col width="" span="1"/>
                        <col width="" span="1"/>
                        <col width="" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="2" colspan="1">Demographic element</th>
                          <th colspan="2" rowspan="1">Value for:<hr/></th>
                        </tr>
                        <tr>
                          <th rowspan="1" colspan="1">Placebo (<italic>n</italic> = 7)</th>
                          <th rowspan="1" colspan="1">Vancomycin (<italic>n</italic> = 8)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Receiving antibiotics at enrollment [no. (%)]</td>
                          <td rowspan="1" colspan="1">2 (29)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Age [yr; median (range)]</td>
                          <td rowspan="1" colspan="1">64 (48–77)</td>
                          <td rowspan="1" colspan="1">66 (37–81)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Female [no. (%)]</td>
                          <td rowspan="1" colspan="1">6 (86)</td>
                          <td rowspan="1" colspan="1">4 (50)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Nonwhite race [no. (%)]</td>
                          <td rowspan="1" colspan="1">1 (14)</td>
                          <td rowspan="1" colspan="1">1 (13)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Comorbidities [no. (%)]</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Diabetes mellitus</td>
                          <td rowspan="1" colspan="1">3 (43)</td>
                          <td rowspan="1" colspan="1">2 (25)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Cancer (excluding leukemia/lymphoma)</td>
                          <td rowspan="1" colspan="1">2 (29)</td>
                          <td rowspan="1" colspan="1">4 (50)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Leukemia/lymphoma</td>
                          <td rowspan="1" colspan="1">4 (57)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Irritable bowel syndrome</td>
                          <td rowspan="1" colspan="1">1 (14)</td>
                          <td rowspan="1" colspan="1">1 (13)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Chemotherapy at enrollment or in previous 4 weeks [no. (%)]</td>
                          <td rowspan="1" colspan="1">5 (71)</td>
                          <td rowspan="1" colspan="1">4 (50)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Laxative within 48 h of stool collection [no. (%)]</td>
                          <td rowspan="1" colspan="1">2 (29)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Laxative within 48 h of study enrollment [no. (%)]</td>
                          <td rowspan="1" colspan="1">2 (29)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Hospitalization(s) in previous year [no. (%)]</td>
                          <td rowspan="1" colspan="1">6 (86)</td>
                          <td rowspan="1" colspan="1">6 (75)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">No. of previous hospitalizations [no. (%)]</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 0</td>
                          <td rowspan="1" colspan="1">1 (14)</td>
                          <td rowspan="1" colspan="1">2 (25)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 1 or 2</td>
                          <td rowspan="1" colspan="1">2 (29)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 3 or more</td>
                          <td rowspan="1" colspan="1">4 (57)</td>
                          <td rowspan="1" colspan="1">3 (38)</td>
                        </tr>
                      </tbody>
                    </table>
                    <graphic xlink:href="mSphere.00936-20_t001"/>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="ngtab1.1">
                      <label>a</label>
                      <p>Patients were randomized based on whether or not they were receiving antibiotics at enrollment.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <supplementary-material content-type="local-data" id="figS1">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.1</object-id>
                  <label>FIG S1</label>
                  <p>Screening enrollment flow chart for double-blinded, randomized controlled <underline>T</underline>rial of <underline>O</underline>ral vancomycin versus placebo in hospitalized patients with diarrhea and stool to<underline>X</underline>in <underline>NEG</underline>ative but nucleic acid amplification test positive for toxigenic <named-content content-type="genus-species">Clostridioides difficile</named-content>. EIA, enzyme immunoassay; NAAT, nucleic acid amplification test; SNF, skilled nursing facility <inline-supplementary-material id="fS1" mimetype="application" mime-subtype="pdf" xlink:href="mSphere.00936-20_sf001.pdf" content-type="local-data">FIG S1, PDF file, 0.7 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="figS2">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.2</object-id>
                  <label>FIG S2</label>
                  <p><bold>(</bold>a) Timeline of patient antimicrobial use. The gray zone indicates the timezone from study enrollment to week 8 for each patient. Amp/Sul, ampicillin-sulbactam; Pip/Tazo, piperacillin-tazobactam; TMP/SMX, trimethoprim-sulfamethoxazole. (b) Relative abundance of microbial taxa at the level of order for a set of patient-time point comparisons, where grouped bar plots indicate microbiomes from different sample types at the same patient-time point. RS, rectal swab; ST, stool. (c) Bray-Curtis dissimilarity distributions for comparisons between microbiomes from the same patient-time point (rectal swab-stool), from different time points within one patient (within patient), and from different patients (between patients). Distances were significantly different between rectal swab-stool and within-patient (****, <italic>P</italic> = 4.2e−9) comparisons, between rectal swab-stool and between patient (****, <italic>P</italic> = 4.2e−9), and between within patient and between patient (****, <italic>P</italic> &lt; 2e−16), as determined by a pairwise Wilcoxon test with a Bonferroni multiple testing correction. (d) Relative abundances of <named-content content-type="genus-species">C. difficile</named-content> in patient microbiomes over time; patient 12 is depicted (green, thick line). Download <inline-supplementary-material id="fS2" mimetype="application" mime-subtype="pdf" xlink:href="mSphere.00936-20_sf002.pdf" content-type="local-data">FIG S2, PDF file, 0.8 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="textS1">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.5</object-id>
                  <label>TEXT S1</label>
                  <p>Extended discussion of study methods and results. Download <inline-supplementary-material id="txS1" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="mSphere.00936-20_stxt01.docx" content-type="local-data">Text S1, DOCX file, 0.03 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
              <sec id="s2.2">
                <title><named-content content-type="genus-species">C. difficile</named-content>-related outcomes and colonization poststudy.</title>
                <p>One patient (vancomycin group) had new/worsening abdominal pain, while one patient’s stool (placebo group) tested positive by toxin EIA (described below). With the CDI-related events described above, 5 patients in total had adverse events, including hypoxemia, vertigo, and altered mental status. The median time to end of clinically significant diarrhea (CSD) was 4 days in the placebo group and 2 days in the vancomycin group (<italic>P = </italic>0.46). Posttreatment, 80% of placebo patients and 71% of vancomycin-treated patients had stool containing culturable <named-content content-type="genus-species">C. difficile</named-content>.</p>
                <p>Patient 12 (placebo group) had persistent diarrhea, and the treating physician ordered repeat <named-content content-type="genus-species">C. difficile</named-content> testing, which returned EIA<sup>+</sup> at the S02 time point. The study blind was broken and the patient was started on oral vancomycin. To better understand this patient’s trajectory, a more thorough investigation of this patient was conducted.</p>
                <p>The patient had been admitted for autologous hematopoietic cell transplantation (HCT) for lymphoma. The patient developed neutropenia, mucositis, and diarrhea when expected based on the HCT conditioning regimen received (carmustine, etoposide, aracytin, and melphalan). This prompted stool collection for <named-content content-type="genus-species">C. difficile</named-content> testing that became the qualifying stool specimen (S00). The diarrhea persisted into the trial, leading the treating clinicians to order repeat testing for <named-content content-type="genus-species">C. difficile</named-content>, and the stool was EIA<sup>+</sup> at day 5. Her diarrhea started to improve 2 days after CDI treatment was started; this also corresponded to neutrophil recovery and improvement in mucositis. Examination of <named-content content-type="genus-species">C. difficile</named-content> levels in the fecal metagenomics revealed that at time S00, patient 12 had 0.15% <named-content content-type="genus-species">C. difficile</named-content> abundance, while the whole patient population had 0 to 1.3% <named-content content-type="genus-species">C. difficile</named-content> abundance (<xref ref-type="supplementary-material" rid="figS2">Fig. S2d</xref>). At S02, patient 12 had 1.5% <named-content content-type="genus-species">C. difficile</named-content> abundance (0 to 1.5% <named-content content-type="genus-species">C. difficile</named-content> abundance in total population).</p>
              </sec>
              <sec id="s2.3">
                <title>Vancomycin effect on gut microbiome and resistome.</title>
                <p>Patient’s microbiomes shifted more significantly in the vancomycin group, as measured by within-patient beta-diversity (<xref ref-type="fig" rid="fig1">Fig. 1b</xref>; <italic>P = </italic>0.005). Alpha-diversity decreased in both groups during treatment; vancomycin did not significantly alter alpha-diversity relative to that of the placebo (<xref ref-type="fig" rid="fig1">Fig. 1c</xref>). We also examined treatment-related perturbations to the gut resistome in a subset of patients (three from each group) using ShortBred to map metagenomic reads to known antibiotic resistance genes (ARGs). We examined changes in the abundance of ARG class markers between the treatment groups (before, S00, and after, S05, treatment) and found that the class of multidrug resistance (MDR) markers decreased by 25% (<italic>P = </italic>0.0071) in the placebo group, the class of genes encoding efflux pump machinery decreased by 55% (<italic>P &lt; </italic>0.0001) in the placebo group, while the class of genes encoding macrolide-lincosamide-streptogramin (MLS) resistance increased by 22% (<italic>P = </italic>0.037) in the vancomycin group (<xref ref-type="fig" rid="fig1">Fig. 1d</xref>). Finally, the relative alpha-diversity of ARGs was significantly increased after treatment in the vancomycin group (<xref ref-type="supplementary-material" rid="figS3">Fig. S3a</xref>; <italic>P = </italic>0.028).</p>
                <supplementary-material content-type="local-data" id="figS3">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.3</object-id>
                  <label>FIG S3</label>
                  <p>(a) Measurement of relative alpha-diversity, or Shannon diversity, for ARG compositition in a subset of patients on vancomycin (blue) or placebo (red). Time points correspond to before (index), during (day 10), and after (week 8) treatment. Shannon diversity was significantly different between treatment groups (<italic>P = </italic>0.028) at week 8, as examined by a Welch’s two-sample <italic>t</italic> test. (b) Approximate-maximum-likelihood tree of 250 <named-content content-type="genus-species">C. difficile</named-content> genomes. ST11 strains are colored green if they were isolated from this cohort and blue if they were previously published ST11 genomes. (c) SNP distances determined from the core-genome alignment of the isolate cohort visualized in <xref ref-type="fig" rid="fig2">Fig. 2a</xref>. ****, <italic>P </italic>&lt; 0.0001, as determined by pairwise Wilcoxon rank sum test, corrected for multiple testing using Bonferroni. Download <inline-supplementary-material id="fS3" mimetype="application" mime-subtype="pdf" xlink:href="mSphere.00936-20_sf003.pdf" content-type="local-data">FIG S3, PDF file, 0.8 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
              <sec id="s2.4">
                <title>Phylogenetic examination of <named-content content-type="genus-species">C. difficile</named-content> to quantify environmental contamination.</title>
                <p>In addition to defining any effects of vancomycin on <named-content content-type="genus-species">C. difficile</named-content>-related outcomes and the microbiome, we examined the <named-content content-type="genus-species">C. difficile</named-content> isolate population to make inferences about pathogenicity and patient shedding. We sequenced 75 <named-content content-type="genus-species">C. difficile</named-content> isolates cultured from patient stools and their environment. A maximum-likelihood tree of the core genome (consisting of 2,628 genes) alignment of our isolates displayed patient-specific clades, indicating that most patients harbored one dominant isolate (<xref ref-type="fig" rid="fig2">Fig. 2a</xref>); multilocus sequence typing (MLST) analysis confirmed that 67% of patient-isolate groups were defined by one sequence type (ST). Notably, patient 12’s ST11 isolates were the only isolates to test positive for the toxin genes <italic>cdtA</italic> and <italic>cdtB</italic> by multiplex PCR (<xref ref-type="fig" rid="fig2">Fig. 2a</xref> and <xref ref-type="supplementary-material" rid="tabS2">Table S2</xref>) (<xref rid="B19" ref-type="bibr">19</xref>). To contextualize our cohort, we used 250 <named-content content-type="genus-species">C. difficile</named-content> genomes representing all known strain types and our 75 isolate genomes to generate a core genome alignment (consisting of 1,961 genes) and computed a maximum-likelihood phylogenetic tree. In both phylogenetic trees, ST11 isolates (from patient 12 and previously published) formed a distinct clade from other isolates (<xref ref-type="supplementary-material" rid="figS3">Fig. S3b</xref>).</p>
                <fig id="fig2" orientation="portrait" position="float">
                  <label>FIG 2</label>
                  <caption>
                    <p>Patient shedding of <named-content content-type="genus-species">C. difficile</named-content> associated with environmental contamination. (a) Approximate maximum-likelihood tree of 75 <named-content content-type="genus-species">C. difficile</named-content> genomes isolated from patient stool and their environment. Each node represents an isolate found from a patient-time point, where the number before the dash represents the patient and letter after the dash represents the source of the isolate (S, stool; BR, bedrail; C, commode), followed by the number representing the time point of isolation. Isolates colored green represent those recovered from the environment. Color strips represent the outcome of NAAT testing for <named-content content-type="genus-species">C. difficile</named-content> toxins (<italic>tcdAB</italic> and <italic>cdtAB</italic>) and <italic>in silico</italic> MLST typing. (b) Distribution of pairwise single-nucleotide polymorphism (SNP) distances for each patient-isolate group. Distances are visually classfied in two ways: by time point, either between time point comparisons (green) or within time point comparisons (blue), and by source, either environmental-only comparisons (●), stool-to-environment comparisons (▲), or stool-only comparisons (■).</p>
                  </caption>
                  <graphic xlink:href="mSphere.00936-20_f002"/>
                </fig>
                <supplementary-material content-type="local-data" id="tabS1">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.6</object-id>
                  <label>TABLE S1</label>
                  <p>ToxNeg study organization. Patient-time point sample information with metadata. Download <inline-supplementary-material id="tS1" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSphere.00936-20_st001.xlsx" content-type="local-data">Table S1, XLSX file, 0.01 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="tabS2">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.7</object-id>
                  <label>TABLE S2</label>
                  <p><named-content content-type="genus-species">C. difficile</named-content> isolate list. Isolates collected from patient and environment with corresponding strain information. Download <inline-supplementary-material id="tS2" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSphere.00936-20_st002.xlsx" content-type="local-data">Table S2, XLSX file, 0.01 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <p>To identify instances of environmental contamination with <named-content content-type="genus-species">C. difficile</named-content> by patients, we determined strain relatedness (single-nucleotide polymorphism [SNP] distances) between stool and environmental isolates in two ways. First, from the core genome alignment (<xref ref-type="fig" rid="fig2">Fig. 2a</xref>), we found that SNP distances between isolates from the same patient-time point (<italic>P &lt; </italic>0.0001) and from the same patient (<italic>P &lt; </italic>0.0001) were significantly lower than between-patient pairwise SNP distances (<xref ref-type="supplementary-material" rid="figS2">Fig. S2c</xref>). In the second approach, quantification of pairwise SNP distances from patient-specific pseudoreference assemblies revealed that all isolates within a patient were less than 6 SNPs apart from one another (<xref ref-type="fig" rid="fig2">Fig. 2b</xref> and <xref ref-type="supplementary-material" rid="tabS3">Table S3</xref>). Fifty-three percent of patients had evidence of environmental contamination with a nearly identical clone (≤2 SNPs) to their corresponding stool isolate. These data indicate that colonized <named-content content-type="genus-species">C. difficile</named-content> patients serve as a source of <named-content content-type="genus-species">C. difficile</named-content> contamination of the hospital environment, regardless of vancomycin treatment.</p>
                <supplementary-material content-type="local-data" id="tabS3">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.8</object-id>
                  <label>TABLE S3</label>
                  <p><named-content content-type="genus-species">C. difficile</named-content> SNP distances. Pairwise <named-content content-type="genus-species">C. difficile</named-content> isolate comparisons using two different methods. Download <inline-supplementary-material id="tS3" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSphere.00936-20_st003.xlsx" content-type="local-data">Table S3, XLSX file, 0.08 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
              <sec id="s2.5">
                <title>ARO colonization of patients and environment.</title>
                <p>Because patients at risk for CDI are also susceptible to ARO colonization/infection, we were interested in identifying the AROs that exist in the patients and in their environment. We collected 57 AR-<italic>Enterobacterales</italic> isolates, 29 VRE isolates, 14 <italic>Pseudomonas</italic> isolates, and 17 other ARO isolates from cultures of patient stool and the environment. Of the 117 isolates collected, 84 were recovered from patient stool and 33 were recovered from the environment. We found the number of ARO isolates recovered from any patient/patient environment varied across patients (<xref ref-type="supplementary-material" rid="figS4">Table S4</xref>, <xref ref-type="supplementary-material" rid="figS4">Fig. S4</xref>a). Antimicrobial susceptibility testing (AST) of 56 <italic>Enterobacterales</italic> isolates from patients’ stools revealed that 46% were resistant to ciprofloxacin, 7% were resistant to cefepime, and 23% were resistant to piperacillin-tazobactam. Sixty-seven percent of patients were colonized by at least one AR-<italic>Enterobacterales</italic> isolate (<xref ref-type="supplementary-material" rid="figS4">Fig. S4b</xref>).</p>
                <supplementary-material content-type="local-data" id="figS4">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.4</object-id>
                  <label>FIG S4</label>
                  <p>(a) Number of isolates associated with each patient during the trial that were <named-content content-type="genus-species">C. difficile</named-content> (CD), <italic>Pseudomonas</italic> spp., vancomycin-resistance enterococci (VRE), or <italic>Enterobacterales</italic>. (b) Antimicrobial susceptibility testing (AST) data for <italic>Enterobacterales</italic> isolates collected from patient stools, where resistance status was determined in accordance with the Clinical and Laboratory Standards Institutes (CLSI) guidelines. The legend above the clustogram indicates the patient, corresponding treatment group, and time point of the isolate. TMP/SMX, trimethoprim-sulfamethoxazole. (c) Composition of genetic resistance elements identified in VRE isolate cohort using AMRfinder. Each row represents summation of abundances of all antibiotic resistance genes (ARGs) in a given resistance class. (d) Relative abundance of <named-content content-type="genus-species">E. faecium</named-content> for all patients with detectable levels, from fecal microbiome measurements shown in <xref ref-type="fig" rid="fig1">Fig. 1</xref>. Circles indicate corresponding isolation of VRE <named-content content-type="genus-species">E. faecium</named-content> at the same time point from the patient’s stool or environment. Download <inline-supplementary-material id="fS4" mimetype="application" mime-subtype="pdf" xlink:href="mSphere.00936-20_sf004.pdf" content-type="local-data">FIG S4, PDF file, 0.3 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
              <sec id="s2.6">
                <title>VRE colonization and patient shedding.</title>
                <p>Treatment of <named-content content-type="genus-species">C. difficile</named-content> patients with oral vancomycin can facilitate VRE colonization in the patient (<xref rid="B20" ref-type="bibr">20</xref>). Of the five patients with VRE isolated from posttreatment time points (S04 and/or S05), three were in the vancomycin group. Visualization of average nucleotide identity (ANI) across VRE isolates (<xref ref-type="fig" rid="fig3">Fig. 3a</xref>) confirmed matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF-MS) identification of isolates (<xref rid="B21" ref-type="bibr">21</xref>), revealing that <named-content content-type="genus-species">E. faecium</named-content> was isolated from the stool/environment of 7 patients, and <named-content content-type="genus-species">E. faecalis</named-content> was only isolated from the stool/environment of patient 2 (vancomycin group). For <named-content content-type="genus-species">E. faecium</named-content> isolates, we aligned core genomes (consisting of 2,115 genes) and constructed a maximum-likelihood phylogenetic tree. Patient-specific clades corresponded to distinct patterns of phenotypic resistance to ampicillin, doxycycline, and linezolid (<xref ref-type="fig" rid="fig3">Fig. 3b</xref>). Genomic ARG analysis indicated that all enterococcal isolates had the essential components of a functional <italic>van</italic> operon (<italic>vanR-vanS-vanH-vanA-vanX</italic>) (<xref rid="B22" ref-type="bibr">22</xref>), with <named-content content-type="genus-species">E. faecalis</named-content> possessing distinct ARGs relative to <named-content content-type="genus-species">E. faecium</named-content> isolates (<xref ref-type="supplementary-material" rid="figS4">Fig. S4c</xref>).</p>
                <fig id="fig3" orientation="portrait" position="float">
                  <label>FIG 3</label>
                  <caption>
                    <p><named-content content-type="genus-species">E. faecium</named-content> isolates associated with VRE patient shedding/environmental contamination. (a) Pairwise average nucleotide identity (ANI) clustogram between <italic>Enterococcus</italic> isolates, where the color of the box indicates ANI between two isolate genomes. (b) Approximate maximum-likelihood phylogenetic tree of <named-content content-type="genus-species">E. faecium</named-content> isolates. Colored boxes indicate antimicrobial susceptibility testing (AST), where resistance status was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. (c) Pairwise SNP distances derived from the core genome alignment. <italic>P</italic> values were generated through a Wilcoxon rank sum test. ****, &lt;0.0001; ***, &lt;0.001.</p>
                  </caption>
                  <graphic xlink:href="mSphere.00936-20_f003"/>
                </fig>
              </sec>
              <sec id="s2.7">
                <title>Environmental contamination via patient shedding of VREs.</title>
                <p>We measured SNP distance as described above to understand patient shedding of clones into the environment. SNP distances from the core genome alignment (<xref ref-type="fig" rid="fig3">Fig. 3c</xref>) indicated that patient-environment isolates from the same time point had significantly lower SNP distances than within-patient distances (<italic>P = </italic>0.001) or between-patient distances (<italic>P &lt; </italic>0.0001). Using pseudoreference assemblies for each patient, all pairwise SNP distances within each patient were ≤8 SNPs (<xref ref-type="supplementary-material" rid="tabS5">Table S5</xref>). Two patients in the vancomycin group shed VRE clones into their environment (0 SNPs between a stool and environmental isolate from the same time point). Additionally, in vancomycin patients (2, 3, and 9), the metagenomic relative abundance of <named-content content-type="genus-species">E. faecium</named-content> peaked at time points where highly related stool/environmental isolates were recovered (<xref ref-type="supplementary-material" rid="figS4">Fig. S4d</xref>).</p>
                <supplementary-material content-type="local-data" id="tabS4">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.9</object-id>
                  <label>TABLE S4</label>
                  <p>ARO isolate and drug susceptibility data. List of ARO isolates collected from patients and environment with corresponding AST data. Download <inline-supplementary-material id="tS4" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSphere.00936-20_st004.xlsx" content-type="local-data">Table S4, XLSX file, 0.03 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="tabS5">
                  <object-id pub-id-type="doi">10.1128/mSphere.00936-20.10</object-id>
                  <label>TABLE S5</label>
                  <p>VRE SNP distances. Pairwise VRE isolate comparisons using two different methods. Download <inline-supplementary-material id="tS5" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSphere.00936-20_st005.xlsx" content-type="local-data">Table S5, XLSX file, 0.01 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2021 Fishbein et al.</copyright-statement>
                    <copyright-year>2021</copyright-year>
                    <copyright-holder>Fishbein et al.</copyright-holder>
                    <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>DISCUSSION</title>
              <p>We examined the risk-benefit of treating EIA<sup>−</sup>/NAAT<sup>+</sup> patients with oral vancomycin by tracking <named-content content-type="genus-species">C. difficile</named-content>-related outcomes, gut microbiota changes, and environmental contamination by <named-content content-type="genus-species">C. difficile</named-content> and AROs in a double-blinded randomized control trial. We observed appreciable differences in the gut microbiome and resistome due to vancomycin, characterized the development of one EIA<sup>+</sup> case, and identified multiple instances of <named-content content-type="genus-species">C. difficile</named-content> and VRE environmental contamination.</p>
              <p>Vancomycin treatment resulted in an increase in beta-diversity within the gut microbiome but did not significantly alter alpha-diversity (species richness) during the trial relative to the placebo group. Interestingly, the median richness in the vancomycin-treated group at day 5 is lower than that of the placebo group, although this difference was not statistically significant. We predict that with an increased sample size, it is possible that we would have the statistical power to detect a difference in alpha-diversity between the treatment groups. More importantly, clinical data concerning the nonstudy trial antibiotics confirm that the placebo group was receiving antibiotics during the trial, perhaps obscuring vancomycin-related changes in alpha-diversity. However, the vancomycin-related perturbations that we did observe, despite high antibiotic exposure, suggest that this antibiotic has a more profound effect on the microbiome than that measured here.</p>
              <p>A purported benefit of vancomycin treatment of colonized patients is reduction in <named-content content-type="genus-species">C. difficile</named-content> burden and, thus, a subsequent reduction in environmental contamination and transmission. Oral vancomycin treatment did not affect poststudy colonization with <named-content content-type="genus-species">C. difficile</named-content>; the majority of patients in both groups had viable <named-content content-type="genus-species">C. difficile</named-content> in their stool. In addition, we found evidence of environmental contamination in both patient groups. Given that vancomycin is also a known risk factor for CDI (<xref rid="B23" ref-type="bibr">23</xref>), our study does not support the notion that oral vancomycin could provide lasting reductions in <named-content content-type="genus-species">C. difficile</named-content> burden or transmission.</p>
              <p>Patient 12 exemplifies the quandary in managing EIA<sup>−</sup>/NAAT<sup>+</sup> patients and the reason this study was conducted. There are three possibilities to explain patient 12: (i) the first EIA was falsely negative for CDI; (ii) the first EIA was a true negative for CDI and the second EIA was a true positive for CDI; and (iii) the second EIA was a false positive for CDI. A detailed review of the clinical, genomics, and metagenomics data demonstrates the challenges in making these distinctions. Metagenomics data revealed an increase in <named-content content-type="genus-species">C. difficile</named-content> burden by S02, supporting a change from EIA<sup>−</sup> to EIA<sup>+</sup>. Whole-genome sequencing (WGS) data identified the patient’s stool <named-content content-type="genus-species">C. difficile</named-content> isolates as an ST11 strain. This strain contains the accessory binary toxin locus, which encodes a toxin of debatable predictive value, and has been associated with CDI at lower fecal concentrations than other <named-content content-type="genus-species">C. difficile</named-content> strains (<xref rid="B24" ref-type="bibr">24</xref><xref ref-type="bibr" rid="B25">–</xref><xref rid="B26" ref-type="bibr">26</xref>). Overall, the patient’s clinical course was consistent with chemotherapy-associated diarrhea, but the timing of CDI treatment onset and improvement in diarrhea confounds the ability to state this conclusively. With these data, we posit that scenario 2 or 3 is more likely than scenario 1. Of note, if this patient did have an initial false-negative EIA for CDI, she did not suffer from any adverse events from delays in initiation of CDI treatment. This EIA<sup>−</sup>/NAAT<sup>+</sup> patient population remains complex and should be investigated further to understand the predictive value of pathogen (such as the <italic>cdtA-cdtB</italic> locus) and microbiome (<named-content content-type="genus-species">C. difficile</named-content> abundance) markers.</p>
              <p>Vancomycin treatment has been reported to select for ARO colonization and shedding in <named-content content-type="genus-species">C. difficile</named-content> patients (<xref rid="B18" ref-type="bibr">18</xref>). We examined VRE <named-content content-type="genus-species">E. faecium</named-content> dynamics in patients and found that all of the environmental isolates for vancomycin patients were found at time points after the start of the study drug. Further, SNP analysis indicated that this environmental contamination was associated with patient shedding. Previous observations indicated that vancomycin selects for the presence of VRE populations in patients (<xref rid="B18" ref-type="bibr">18</xref>), yet the stool abundance of VREs in those data decreased 2 weeks after treatment; our analyses reveal a different time course of treatment and shedding. In 3 vancomycin-treated patients, <named-content content-type="genus-species">E. faecium</named-content> levels were decreased in the gut during treatment, followed by subsequent <named-content content-type="genus-species">E. faecium</named-content> blooms and patient shedding of VRE strains as far out as 8 weeks after initiation of treatment in some cases. While previous studies have indicated that oral vancomycin could be used prophylactically to prevent CDI (<xref rid="B27" ref-type="bibr">27</xref>), our data indicate that it could select for long-term VRE shedding and colonization.</p>
              <p>Within this cohort, we examined the effects of vancomycin on patients with EIA<sup>−</sup>/NAAT<sup>+</sup> stool to better understand the potential risks and benefits of CDI treatment in these patients. The greatest limitation of this study was the small sample size (see <xref ref-type="supplementary-material" rid="textS1">Text S1</xref> in the supplemental material). However, one patient randomized to placebo had a subsequently EIA<sup>+</sup> stool and was started on CDI treatment. An in-depth evaluation of this patient found that an increasing <named-content content-type="genus-species">C. difficile</named-content> burden from enrollment to midtreatment resulted in an EIA<sup>−</sup> to EIA<sup>+</sup> status. Conversely, our study failed to demonstrate evidence for oral vancomycin decreasing <named-content content-type="genus-species">C. difficile</named-content> environmental contamination and the potential of transmission, another purported benefit to treating this patient population. Further, vancomycin did shift gut microbial communities, altered the gut resistome, and was associated with environmental contamination by VRE. Based on our observations, the use of oral vancomycin as a prophylaxis may not be beneficial given its short-term effect on <named-content content-type="genus-species">C. difficile</named-content> colonization and its protracted effect on patient shedding of VRE. Additionally, diagnosis of CDI remains a significant clinical challenge; additional work is needed to better define the impact CDI treatment has on EIA<sup>−</sup>/NAAT<sup>+</sup> patients as well as the development of diagnostics to improve the predictive values of current diagnostics.</p>
            </sec>
            <sec sec-type="materials|methods" id="s4">
              <title>MATERIALS AND METHODS</title>
              <sec id="s4.1">
                <title>Study design.</title>
                <p>This study was a double-blinded, randomized controlled trial of 10 days of oral vancomycin (125 mg 4 times per day) versus matching placebo for patients with EIA<sup>−</sup>/NAAT<sup>+</sup> stool. It was conducted at Barnes Jewish Hospital (BJH) from November 2017 to January 2019.</p>
              </sec>
              <sec id="s4.2">
                <title>Study population.</title>
                <p>To be eligible, patients had to be admitted to BJH and have at least one diarrheal stool collected that tested negative for <named-content content-type="genus-species">C. difficile</named-content> toxins via EIA (<named-content content-type="genus-species">C. difficile</named-content> Tox A/B II; Alere, Waltham, MA) by the BJH clinical microbiology laboratory. The stool of potentially eligible patients who did not meet any exclusion criteria (see <xref ref-type="supplementary-material" rid="textS1">Text S1</xref> in the supplemental material) was tested by NAAT (Xpert <named-content content-type="genus-species">C. difficile</named-content>; Cepheid, Sunnyvale, CA). Patients whose stool was EIA<sup>−</sup>/NAAT<sup>+</sup> were approached to participate in the study. All study participants provided written, informed consent. This study (registry number NCT03388268) was approved by the Washington University in St. Louis Institutional Review Board, and the study trial is deposited at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>.</p>
              </sec>
              <sec id="s4.3">
                <title>Randomization.</title>
                <p>Patients were randomly assigned in a 1:1 ratio to treatment groups using permutation blocks (<italic>n</italic> = 4 per block), stratified by concomitant nonstudy drug antimicrobial use. All study personnel except the study pharmacist were blinded to treatment assignment.</p>
              </sec>
              <sec id="s4.4">
                <title>Study procedure.</title>
                <p>The qualifying stool specimen (S00) was originally collected during inpatient clinical care, but patients could complete the study as either inpatient or outpatient participants. After enrollment, patients were contacted daily while on the study drug to determine bowel movement consistency and frequency and any new medication exposures and were assessed for adverse events, including diagnosis of CDI. Stool collection and environmental sampling were performed at enrollment (S01), day 5 (S02), day 10 (S03), week 4 (S04), and week 8 (S05) (<xref ref-type="supplementary-material" rid="textS1">Text S1</xref>).</p>
              </sec>
              <sec id="s4.5">
                <title>Bacterial culturing and isolate DNA extraction.</title>
                <p>To determine a subset of the bacterial microbiota present in each stool specimen, 100 μl of 10-fold dilutions of fecal specimens was plated on blood (BD, Franklin Lakes, NJ) and anaerobic brucella blood (Anaerobe Systems, Morgan Hill, CA) agars for growth of nonfastidious Gram-positive and Gram-negative organisms. Additionally, fecal specimens were plated to MacConkey (MAC) agar with cefotaxime, MAC agar with ciprofloxacin (Hardy Diagnostics, Santa Maria, CA), and VRE ChromID agar (bioMérieux, Durham, NC) to isolate extended-spectrum beta lactamase-producing Gram-negative organisms, Gram-negative quinolone-resistant organisms, and VRE (bioMérieux, Durham, NC), respectively. Plates were incubated at 35°C under aerobic conditions (except in the case of anaerobic brucella blood agar) for 14 h. Individual bacterial colonies from the selective media were identified by MALDI-TOF MS (bioMérieux Vitek MS), and antimicrobial susceptibility testing (AST) was performed using Kirby-Bauer disk diffusion and interpreted using CLSI standards. DNA extraction was performed as previously described (<xref rid="B28" ref-type="bibr">28</xref>). <named-content content-type="genus-species">C. difficile</named-content> was cultured anaerobically and isolated (with ribotyping and toxin gene detection performed) as previously described (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Environmental eswabs were collected using the Eswab specimen collection and transport device; the eswabs were vortexed in eluate briefly, and 100 μl eluate was inoculated on the media described above. Aliquots of isolated organisms were frozen at −80°C in 20% glycerol.</p>
              </sec>
              <sec id="s4.6">
                <title>Library preparation and sequencing of metagenomes and isolate genomes.</title>
                <p>Illumina libraries of fecal metagenomic DNA, <named-content content-type="genus-species">C. difficile</named-content> isolate DNA, and VRE isolate DNA were prepared as described previously (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Reads for both metagenomes and isolate genomes were processed and filtered as described previously (<xref ref-type="supplementary-material" rid="textS1">Text S1</xref>) (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p>
              </sec>
              <sec id="s4.7">
                <title>Metagenomic sequencing analysis.</title>
                <p>Species relative abundances were calculated using MetaPhlAn v.2.0 (<xref rid="B33" ref-type="bibr">33</xref>). For patients 7, 8, 10, 11, 13, and 15, at time points S00, S03, and S05, resistance gene abundances were calculated using ShortBRED (<xref rid="B34" ref-type="bibr">34</xref>) and the comprehensive antibiotic resistance database (CARD) (<xref rid="B35" ref-type="bibr">35</xref>). Specifically, <italic>shortbred_quantify.py</italic> was used to determine relative abundances of ARGs based on metagenomics reads. Both species and gene abundances were imported into R using custom Python scripts. The relative abundance of ARG class was calculated as follows. For each patient and each ARG class, ARG read per kilobase per million (RPKM) counts were summed within a class and divided by a patient’s total RPKMs (derived from ShortBRED) to obtain the relative abundance of an antimicrobial resistance gene class. For each group, relative abundances of ARG class were averaged across patients for visualization.</p>
              </sec>
              <sec id="s4.8">
                <title>Whole-genome sequencing and analysis.</title>
                <p>Draft genomes were <italic>de novo</italic> assembled into contigs using SPAdes v3.13.0 (<xref rid="B36" ref-type="bibr">36</xref>) and assessed for quality using QUAST (<xref rid="B37" ref-type="bibr">37</xref>). For downstream analysis, all genome assemblies were required to have &lt;250 contigs and &gt;40× coverage. Using the draft assemblies, we used Prokka v1.12 (<xref rid="B38" ref-type="bibr">38</xref>) to annotate <named-content content-type="genus-species">C. difficile</named-content> and VRE genomes. <italic>In silico</italic> multilocus sequence typing (MLST) was performed on all genomes (<ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/mlst">https://github.com/tseemann/mlst</ext-link>). For each organism, using the .gff files generated by Prokka, a core genome alignment was generated via Roary v3.12.0 (<xref rid="B39" ref-type="bibr">39</xref>), and an approximate maximum-likelihood tree was calculated using FastTree v2.1.10 (<xref rid="B40" ref-type="bibr">40</xref>). The resulting .newick file was visualized and annotated using iToL (<xref rid="B41" ref-type="bibr">41</xref>). VRE isolate genomes were also analyzed by pyANI (<ext-link ext-link-type="uri" xlink:href="https://github.com/widdowquinn/Pyani">https://github.com/widdowquinn/Pyani</ext-link>) to confirm species differences. Resistance genes in VRE isolates were identified by analyzing the Prokka-generated .gff files using AMRfinder (<xref rid="B42" ref-type="bibr">42</xref>).</p>
              </sec>
              <sec id="s4.9">
                <title>SNP analysis.</title>
                <p>Using the Roary-generated core genome alignments, we computed pairwise SNP distances for all <named-content content-type="genus-species">C. difficile</named-content> and VRE <named-content content-type="genus-species">E. faecium</named-content> isolates using SNP-sites (<xref rid="B43" ref-type="bibr">43</xref>). To examine within-patient relatedness, we defined patient groups of strains, whereby all strains (from this study) were the same ST or had &lt;300 SNPs according to our core genome SNP analysis. For each strain group consisting of <italic>n</italic> isolates, we subsampled reads from a given isolate to achieve &gt;75× coverage across the genome. Using these subsampled isolate reads, we generated a pseudoreference assembly for each patient and called SNPs by mapping nonsubsampled quality filtered forward and reverse reads to each assembly using Snippy v4.3.8 (<ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/snippy">https://github.com/tseemann/snippy</ext-link>). Using the output .bam files, we used Samtools (<xref rid="B44" ref-type="bibr">44</xref>) <italic>mpileup -q30</italic> and bcftools view, filtering with <italic>–i 'DP &gt; 10 &amp; QS &gt; 0.95'</italic>, <italic>'FQ&lt;-85' –exclude-types indels</italic>, to generate VCF files for each patient-time point. VCF files were merged, and pairwise SNP distances were computed and visualized in R.</p>
              </sec>
              <sec id="s4.10">
                <title>Data and statistical analysis.</title>
                <p>Treatment difference in time to resolution of CSD was computed using a Mann-Whitney U test. Percent change in ARG class abundance was obtained by normalizing relative abundances by the corresponding relative abundance at S00. Statistically significant differences in percent change between vancomycin and placebo groups were determined using a Student's <italic>t</italic> test and corrected for multiple testing using the Holm-Sidak method. For visualization of metagenomics data and computation of community diversity statistics, the packages <italic>phyloseq</italic> and <italic>vegan</italic> were used in R. For visualization of heatmaps concerning AST/ARG profiles, the package <italic>pheatmap</italic> was used. All other statistical tests are described in the figure legends.</p>
              </sec>
              <sec id="s4.11">
                <title>Data availability.</title>
                <p>All genomic sequences and metagenomics sequences were deposited in NCBI under BioProject no. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA646752" assigning-authority="bioproject">PRJNA646752</ext-link>.</p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p>For commentary on this article, see <related-article related-article-type="companion" id="d39e1657" ext-link-type="doi" xlink:href="10.1128/mSphere.01296-20" vol="6">https://doi.org/10.1128/mSphere.01296-20</related-article>.</p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank the patients and study team for their participation in this trial. We also thank the study pharmacist, Kristopher Bakos, for his participation in the study. We are grateful to members of the Dantas laboratory for their helpful feedback on the manuscript. We also thank the Edison Family Center for Genome Sciences and Systems Biology staff, Eric Martin, Brian Koebbe, MariaLynn Crosby, and Jessica Hoisington-López, for their expertise and support in sequencing/data analysis.</p>
              <p>E.R.D. has received research support from Pfizer and Ferring and has been a consultant for Merck, Ferring, Pfizer, and Seres Therapeutics, all unrelated to this study. The other authors have no conflicts of interest.</p>
              <p>This work was supported in part by awards to E.R.D. from the CDC (Broad Agency Announcement, contract 200-2017-96178). G.D. received support from the National Center for Complementary and Integrative Health (NCCIH; <ext-link ext-link-type="uri" xlink:href="https://nccih.nih.gov/">https://nccih.nih.gov/</ext-link>) of the National Institutes of Health (NIH) under award number R01AT009741; the National Institute for Occupational Safety and Health (NIOSH; <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/niosh/index.htm">https://www.cdc.gov/niosh/index.htm</ext-link>) of the U.S. Centers for Disease Control and Prevention (CDC) under award number R01OH011578l; and the Congressionally Directed Medical Research Program (CDMRP; <ext-link ext-link-type="uri" xlink:href="https://cdmrp.army.mil/prmrp/default">https://cdmrp.army.mil/prmrp/default</ext-link>) of the U.S. Department of Defense (DOD under award number W81XWH1810225). J.H.K. is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number 1K23AI137321. S.R.S.F. is supported by the National Institute of Child Health and Human Development (NICHD; <ext-link ext-link-type="uri" xlink:href="https://www.nichd.nih.gov/">https://www.nichd.nih.gov/</ext-link>) of the NIH under award number T32 HD004010.</p>
              <p>The conclusions from this study represent those of the authors and do not represent positions of the funding agencies.</p>
            </ack>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guh</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Winston</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Holzbauer</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Phipps</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Dumyati</surname><given-names>GK</given-names></name>, <name name-style="western"><surname>Beldavs</surname><given-names>ZG</given-names></name>, <name name-style="western"><surname>Kainer</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>LC</given-names></name></person-group>, <collab>Emerging Infections Program Clostridioides difficile Infection Working Group</collab>. <year>2020</year><article-title>Trends in U.S. burden of Clostridioides difficile infection and outcomes</article-title>. <source>N Engl J Med</source><volume>382</volume>:<fpage>1320</fpage>–<lpage>1330</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1910215</pub-id>.<pub-id pub-id-type="pmid">32242357</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eze</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Balsells</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kyaw</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>H</given-names></name></person-group><year>2017</year><article-title>Risk factors for Clostridium difficile infections—an overview of the evidence base and challenges in data synthesis</article-title>. <source>J Glob Health</source><volume>7</volume>:<fpage>010417</fpage>. doi:<pub-id pub-id-type="doi">10.7189/jogh.07.010417</pub-id>.<pub-id pub-id-type="pmid">28607673</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Peck</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Joo</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Ha</surname><given-names>YE</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>NY</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>JH</given-names></name></person-group><year>2013</year><article-title>Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital</article-title>. <source>Int J Infect Dis</source><volume>17</volume>:<fpage>e240</fpage>–<lpage>e246</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2012.09.019</pub-id>.<pub-id pub-id-type="pmid">23195640</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mody</surname><given-names>L</given-names></name></person-group><year>2015</year><article-title>Colonization with multi-drug resistant organisms in nursing homes: scope, importance, and management</article-title>. <source>Curr Geriatr Rep</source><volume>4</volume>:<fpage>87</fpage>–<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13670-015-0120-2</pub-id>.<pub-id pub-id-type="pmid">25664233</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Muto</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Owens</surname><given-names>RC</given-names><suffix>Jr</suffix></name></person-group><year>2008</year><article-title>Measures to control and prevent Clostridium difficile infection</article-title>. <source>Clin Infect Dis</source><volume>46</volume>(<issue>Suppl 1</issue>):<fpage>S43</fpage>–<lpage>S49</lpage>. doi:<pub-id pub-id-type="doi">10.1086/521861</pub-id>.<pub-id pub-id-type="pmid">18177221</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Monaghan</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>MH</given-names></name></person-group><year>2016</year><article-title>Clostridium difficile infection: epidemiology, diagnosis and understanding transmission</article-title>. <source>Nat Rev Gastroenterol Hepatol</source><volume>13</volume>:<fpage>206</fpage>–<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrgastro.2016.25</pub-id>.<pub-id pub-id-type="pmid">26956066</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>KC</given-names></name></person-group><year>2013</year><article-title>Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories</article-title>. <source>Clin Microbiol Rev</source><volume>26</volume>:<fpage>604</fpage>–<lpage>630</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00016-13</pub-id>.<pub-id pub-id-type="pmid">23824374</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koo</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Van</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Revell</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>ZD</given-names></name>, <name name-style="western"><surname>Grimes</surname><given-names>CZ</given-names></name>, <name name-style="western"><surname>Koo</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Lasco</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kozinetz</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Garey</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>DuPont</surname><given-names>HL</given-names></name></person-group><year>2014</year><article-title>Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates</article-title>. <source>Infect Control Hosp Epidemiol</source><volume>35</volume>:<fpage>667</fpage>–<lpage>673</lpage>. doi:<pub-id pub-id-type="doi">10.1086/676433</pub-id>.<pub-id pub-id-type="pmid">24799643</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Champagne</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hinch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lloyd-Smith</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Romney</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lowe</surname><given-names>CF</given-names></name></person-group><year>2018</year><article-title>Clinical heterogeneity of patients with stool samples testing PCR+/Tox- from a two-step Clostridium difficile diagnostic algorithm</article-title>. <source>Eur J Clin Microbiol Infect Dis</source><volume>37</volume>:<fpage>2355</fpage>–<lpage>2359</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10096-018-3383-7</pub-id>.<pub-id pub-id-type="pmid">30238342</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckel</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Avdic</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Gunaseelan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hadhazy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cosgrove</surname><given-names>SE</given-names></name></person-group><year>2015</year><article-title>Gut check: Clostridium difficile testing and treatment in the molecular testing era</article-title>. <source>Infect Control Hosp Epidemiol</source><volume>36</volume>:<fpage>217</fpage>–<lpage>221</lpage>. doi:<pub-id pub-id-type="doi">10.1017/ice.2014.19</pub-id>.<pub-id pub-id-type="pmid">25633006</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Sarwal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feinstein</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hennessey</surname><given-names>K</given-names></name></person-group><year>2019</year><article-title>Effective dosage of oral vancomycin in treatment for initial episode of Clostridioides difficile infection: a systematic review and meta-analysis</article-title>. <source>Antibiotics (Basel)</source><volume>8</volume>:<fpage>173</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics8040173</pub-id>.</mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayedy</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kothari</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>RJ</given-names></name></person-group><year>2010</year><article-title>Toxic megacolon associated Clostridium difficile colitis</article-title>. <source>World J Gastrointest Endosc</source><volume>2</volume>:<fpage>293</fpage>–<lpage>297</lpage>. doi:<pub-id pub-id-type="doi">10.4253/wjge.v2.i8.293</pub-id>.<pub-id pub-id-type="pmid">21160629</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Homann</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Bettin</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Quick</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Clabots</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Gerding</surname><given-names>DN</given-names></name></person-group><year>1992</year><article-title>Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial</article-title>. <source>Ann Intern Med</source><volume>117</volume>:<fpage>297</fpage>–<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-117-4-297</pub-id>.<pub-id pub-id-type="pmid">1322075</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacPherson</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Mathieu</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Tremblay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Champagne</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nantel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Girard</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Tompkins</surname><given-names>TA</given-names></name></person-group><year>2018</year><article-title>Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults</article-title>. <source>Sci Rep</source><volume>8</volume>:<fpage>11192</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-29229-5</pub-id>.<pub-id pub-id-type="pmid">30046129</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rettedal</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>van der Helm</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ellabaan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Panagiotou</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sommer</surname><given-names>MOA</given-names></name></person-group><year>2019</year><article-title>Antibiotic treatment drives the diversification of the human gut resistome</article-title>. <source>Genomics Proteomics Bioinformatics</source><volume>17</volume>:<fpage>39</fpage>–<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.gpb.2018.12.003</pub-id>.<pub-id pub-id-type="pmid">31026582</pub-id></mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Konishi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Aoki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ishii</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chono</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tateda</surname><given-names>K</given-names></name></person-group><year>2020</year><article-title>The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin</article-title>. <source>J Infect Chemother</source><volume>26</volume>:<fpage>483</fpage>–<lpage>491</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jiac.2019.12.020</pub-id>.<pub-id pub-id-type="pmid">32165071</pub-id></mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Al-Nassir</surname><given-names>WN</given-names></name>, <name name-style="western"><surname>Nerandzic</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><year>2009</year><article-title>Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease</article-title>. <source>Infect Control Hosp Epidemiol</source><volume>30</volume>:<fpage>13</fpage>–<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1086/592710</pub-id>.<pub-id pub-id-type="pmid">19046063</pub-id></mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Nassir</surname><given-names>WN</given-names></name>, <name name-style="western"><surname>Sethi</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pultz</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Riggs</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><year>2008</year><article-title>Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease</article-title>. <source>Antimicrob Agents Chemother</source><volume>52</volume>:<fpage>2403</fpage>–<lpage>2406</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00090-08</pub-id>.<pub-id pub-id-type="pmid">18443120</pub-id></mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goorhuis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bakker</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Corver</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Debast</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Harmanus</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Notermans</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Bergwerff</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Dekker</surname><given-names>FW</given-names></name>, <name name-style="western"><surname>Kuijper</surname><given-names>EJ</given-names></name></person-group><year>2008</year><article-title>Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078</article-title>. <source>Clin Infect Dis</source><volume>47</volume>:<fpage>1162</fpage>–<lpage>1170</lpage>. doi:<pub-id pub-id-type="doi">10.1086/592257</pub-id>.<pub-id pub-id-type="pmid">18808358</pub-id></mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nerandzic</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Mullane</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Babakhani</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Donskey</surname><given-names>CJ</given-names></name></person-group><year>2012</year><article-title>Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection</article-title>. <source>Clin Infect Dis</source><volume>55</volume>:<fpage>S121</fpage>–<lpage>S126</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cis440</pub-id>.<pub-id pub-id-type="pmid">22752860</pub-id></mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McElvania Tekippe</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Shuey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Winkler</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name></person-group><year>2013</year><article-title>Optimizing identification of clinically relevant Gram-positive organisms by use of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system</article-title>. <source>J Clin Microbiol</source><volume>51</volume>:<fpage>1421</fpage>–<lpage>1427</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.02680-12</pub-id>.<pub-id pub-id-type="pmid">23426925</pub-id></mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Krause</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Blais</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Benton</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Mammen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Humphrey</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Kinana</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Janc</surname><given-names>JW</given-names></name></person-group><year>2010</year><article-title>Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin</article-title>. <source>Antimicrob Agents Chemother</source><volume>54</volume>:<fpage>2814</fpage>–<lpage>2818</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01737-09</pub-id>.<pub-id pub-id-type="pmid">20404117</pub-id></mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name></person-group><year>2019</year><article-title>Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China</article-title>. <source>BMC Infect Dis</source><volume>19</volume>:<fpage>961</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-019-4603-1</pub-id>.<pub-id pub-id-type="pmid">31711425</pub-id></mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilate</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Verhaegen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Van Ranst</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Saegeman</surname><given-names>V</given-names></name></person-group><year>2016</year><article-title>Binary toxin and its clinical importance in Clostridium difficile infection, Belgium</article-title>. <source>Eur J Clin Microbiol Infect Dis</source><volume>35</volume>:<fpage>1741</fpage>–<lpage>1747</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10096-016-2719-4</pub-id>.<pub-id pub-id-type="pmid">27393490</pub-id></mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Berg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hegarty</surname><given-names>J</given-names></name></person-group><year>2013</year><article-title>Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key</article-title>. <source>J Gastrointest Surg</source><volume>17</volume>:<fpage>118</fpage>–<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11605-012-2056-6</pub-id>.<pub-id pub-id-type="pmid">23086451</pub-id></mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knetsch</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Connor</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Mutreja</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van Dorp</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Browne</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lipman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Keessen</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Corver</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kuijper</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Lawley</surname><given-names>TD</given-names></name></person-group><year>2014</year><article-title>Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands, 2002 to 2011</article-title>. <source>Euro Surveill</source><volume>19</volume>:<fpage>20954</fpage>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917.es2014.19.45.20954</pub-id>.<pub-id pub-id-type="pmid">25411691</pub-id></mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Priest</surname><given-names>DH</given-names></name></person-group><year>2019</year><article-title>Effectiveness of oral vancomycin for prevention of healthcare facility-onset Clostridioides difficile infection in targeted patients during systemic antibiotic exposure</article-title>. <source>Clin Infect Dis</source><volume>71</volume>:<fpage>1133</fpage>–<lpage>1139</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz966</pub-id>.</mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Souza</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Potter</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shupe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Gul</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Andleeb</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Dantas</surname><given-names>G</given-names></name></person-group><year>2019</year><article-title>Spatiotemporal dynamics of multidrug resistant bacteria on intensive care unit surfaces</article-title>. <source>Nat Commun</source><volume>10</volume>:<fpage>4569</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-12563-1</pub-id>.<pub-id pub-id-type="pmid">31594927</pub-id></mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hink</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Dubberke</surname><given-names>ER</given-names></name></person-group><year>2013</year><article-title>A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens</article-title>. <source>Anaerobe</source><volume>19</volume>:<fpage>39</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.anaerobe.2012.12.001</pub-id>.<pub-id pub-id-type="pmid">23247066</pub-id></mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westblade</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Chamberland</surname><given-names>RR</given-names></name>, <name name-style="western"><surname>MacCannell</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dubberke</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Dunne</surname><given-names>WM</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name></person-group><year>2013</year><article-title>Development and evaluation of a novel, semiautomated Clostridium difficile typing platform</article-title>. <source>J Clin Microbiol</source><volume>51</volume>:<fpage>621</fpage>–<lpage>624</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.02627-12</pub-id>.<pub-id pub-id-type="pmid">23175261</pub-id></mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Hink</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shaikh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wollam</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sodergren</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Weinstock</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Tarr</surname><given-names>PI</given-names></name>, <name name-style="western"><surname>Dubberke</surname><given-names>ER</given-names></name></person-group><year>2014</year><article-title>Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study</article-title>. <source>J Clin Microbiol</source><volume>52</volume>:<fpage>4260</fpage>–<lpage>4266</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.02115-14</pub-id>.<pub-id pub-id-type="pmid">25275005</pub-id></mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D’Souza</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Moodley-Govender</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Berla</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kelkar</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Daniels</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Coutsoudis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Trehan</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Dantas</surname><given-names>G</given-names></name></person-group><year>2019</year><article-title>Cotrimoxazole prophylaxis increases resistance gene prevalence and alpha-diversity but decreases beta-diversity in the gut microbiome of HIV-exposed uninfected infants</article-title>. <source>Clin Infect Dis</source><volume>13</volume>:<fpage>ciz1186</fpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz1186</pub-id>.</mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segata</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Waldron</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ballarini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Narasimhan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Jousson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Huttenhower</surname><given-names>C</given-names></name></person-group><year>2012</year><article-title>Metagenomic microbial community profiling using unique clade-specific marker genes</article-title>. <source>Nat Methods</source><volume>9</volume>:<fpage>811</fpage>–<lpage>814</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nmeth.2066</pub-id>.<pub-id pub-id-type="pmid">22688413</pub-id></mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Franzosa</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Segata</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dantas</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Huttenhower</surname><given-names>C</given-names></name></person-group><year>2015</year><article-title>High-specificity targeted functional profiling in microbial communities with ShortBRED</article-title>. <source>PLoS Comput Biol</source><volume>11</volume>:<elocation-id>e1004557</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004557</pub-id>.<pub-id pub-id-type="pmid">26682918</pub-id></mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McArthur</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Waglechner</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nizam</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Azad</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Baylay</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Bhullar</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Canova</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>De Pascale</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ejim</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kalan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>King</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Koteva</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Morar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mulvey</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Pawlowski</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Piddock</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Spanogiannopoulos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sutherland</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Thaker</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>GD</given-names></name></person-group><year>2013</year><article-title>The comprehensive antibiotic resistance database</article-title>. <source>Antimicrob Agents Chemother</source><volume>57</volume>:<fpage>3348</fpage>–<lpage>3357</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00419-13</pub-id>.<pub-id pub-id-type="pmid">23650175</pub-id></mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bankevich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nurk</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Antipov</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gurevich</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Dvorkin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kulikov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Lesin</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Nikolenko</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Prjibelski</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Pyshkin</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Sirotkin</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Vyahhi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tesler</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Alekseyev</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Pevzner</surname><given-names>PA</given-names></name></person-group><year>2012</year><article-title>SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing</article-title>. <source>J Comput Biol</source><volume>19</volume>:<fpage>455</fpage>–<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id>.<pub-id pub-id-type="pmid">22506599</pub-id></mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurevich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Saveliev</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Vyahhi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tesler</surname><given-names>G</given-names></name></person-group><year>2013</year><article-title>QUAST: quality assessment tool for genome assemblies</article-title>. <source>Bioinformatics</source><volume>29</volume>:<fpage>1072</fpage>–<lpage>1075</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btt086</pub-id>.<pub-id pub-id-type="pmid">23422339</pub-id></mixed-citation>
              </ref>
              <ref id="B38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ono</surname><given-names>Y</given-names></name></person-group><year>1989</year><article-title>Synchronous and sequential activation of latently infected Epstein-Barr virus genomes</article-title>. <source>J Virol</source><volume>63</volume>:<fpage>445</fpage>–<lpage>449</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.63.1.445-449.1989</pub-id>.<pub-id pub-id-type="pmid">2462063</pub-id></mixed-citation>
              </ref>
              <ref id="B39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asherson</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Colizzi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Zembala</surname><given-names>M</given-names></name>, <name name-style="western"><surname>James</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Watkins</surname><given-names>MC</given-names></name></person-group><year>1984</year><article-title>Nonspecific inhibitor of contact sensitivity made by T-acceptor cells: triggering of T cells armed with antigen-specific T-suppressor factor (TsF) requires both occupancy of the major histocompatibility complex recognition site by soluble I-J product and cross-linking of the antigen recognition sites of the TsF</article-title>. <source>Cell Immunol</source><volume>83</volume>:<fpage>389</fpage>–<lpage>397</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0008-8749(84)90318-6</pub-id>.<pub-id pub-id-type="pmid">6198102</pub-id></mixed-citation>
              </ref>
              <ref id="B40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Dehal</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Arkin</surname><given-names>AP</given-names></name></person-group><year>2010</year><article-title>FastTree 2–approximately maximum-likelihood trees for large alignments</article-title>. <source>PLoS One</source><volume>5</volume>:<elocation-id>e9490</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0009490</pub-id>.<pub-id pub-id-type="pmid">20224823</pub-id></mixed-citation>
              </ref>
              <ref id="B41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Letunic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bork</surname><given-names>P</given-names></name></person-group><year>2019</year><article-title>Interactive Tree Of Life (iTOL) v4: recent updates and new developments</article-title>. <source>Nucleic Acids Res</source><volume>47</volume>:<fpage>W256</fpage>–<lpage>W259</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz239</pub-id>.<pub-id pub-id-type="pmid">30931475</pub-id></mixed-citation>
              </ref>
              <ref id="B42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldgarden</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brover</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Haft</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Slotta</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Tolstoy</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Tyson</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>McDermott</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Tadesse</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Morales</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Simmons</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tillman</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wasilenko</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Folster</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Klimke</surname><given-names>W</given-names></name></person-group><year>2019</year><article-title>Validating the AMRFinder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates</article-title>. <source>Antimicrob Agents Chemother</source><volume>63</volume>:<elocation-id>e00483-19</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00483-19</pub-id>.<pub-id pub-id-type="pmid">31427293</pub-id></mixed-citation>
              </ref>
              <ref id="B43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Delaney</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Soares</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Seemann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Keane</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>SR</given-names></name></person-group><year>2016</year><article-title>SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments</article-title>. <source>Microb Genom</source><volume>2</volume>:<elocation-id>e000056</elocation-id>. doi:<pub-id pub-id-type="doi">10.1099/mgen.0.000056</pub-id>.<pub-id pub-id-type="pmid">28348851</pub-id></mixed-citation>
              </ref>
              <ref id="B44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Handsaker</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wysoker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fennell</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Homer</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Marth</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Durbin</surname><given-names>R</given-names></name></person-group>, <collab>Genome Project Data Processing Subgroup</collab>. <year>2009</year><article-title>The Sequence Alignment/Map format and SAMtools</article-title>. <source>Bioinformatics</source><volume>25</volume>:<fpage>2078</fpage>–<lpage>2079</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id>.<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
